Akeso Inc
HKEX:9926
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
31.8
74.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Akeso Inc
Akeso Inc
Revenue
Akeso Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Akeso Inc
HKEX:9926
|
Revenue
¥4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
337%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥17.4B
|
CAGR 3-Years
102%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Revenue
¥8.3B
|
CAGR 3-Years
37%
|
CAGR 5-Years
31%
|
CAGR 10-Years
27%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
¥46.7B
|
CAGR 3-Years
30%
|
CAGR 5-Years
42%
|
CAGR 10-Years
51%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Revenue
¥2.9B
|
CAGR 3-Years
59%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
Akeso Inc
Glance View
Akeso Inc. is an innovative biopharmaceutical company that has carved out a distinctive niche in the treatment of cancer and autoimmune diseases. With its headquarters in Zhuhai, China, Akeso is focused on developing cutting-edge therapies driven by its proprietary bispecific antibody platform. This platform allows the company to create multifunctional antibodies that can simultaneously target different pathways, potentially enhancing the effectiveness of treatments while minimizing side effects. Akeso's lead product, the PD-1 monoclonal antibody, AK104, has been making significant strides with promising results in clinical trials, positioning the company as a formidable player in the competitive oncology landscape. As the global demand for novel therapeutics grows, Akeso is not just resting on its laurels. The company has an impressive pipeline of candidates that address various hematological malignancies and autoimmune disorders, indicating a strong commitment to broadening its therapeutic reach. Additionally, Akeso's strategic partnerships, including collaborations with major global pharmaceutical firms for development and commercialization, bolster its potential for growth and market penetration. For investors, Akeso represents a compelling opportunity as it navigates the complexities of drug development and regulatory approval, poised to transform the landscape of treatment options available to patients and carve out a lasting presence in the biopharmaceutical sector.
See Also
What is Akeso Inc's Revenue?
Revenue
4.5B
CNY
Based on the financial report for Dec 31, 2023, Akeso Inc's Revenue amounts to 4.5B CNY.
What is Akeso Inc's Revenue growth rate?
Revenue CAGR 5Y
337%
Over the last year, the Revenue growth was 440%.
You don't have any saved screeners yet
